Advertisement

Topics

Bristol-Myers Squibb And Nektar To Collaborate On Immuno-Oncology Program

08:57 EST 15 Feb 2018 | Pharmaceutical Processing

Under the collaboration, Bristol-Myers Squibb will pay Nektar Therapeutics $1.85 billion upfront. The companies will jointly develop and commercialize NKTR-214 in combination with Bristol-Myers Squibb’s Opdivo and Opdivo plus Yervoy.
Contributed Author: 
Bristol-Myers Squibb Company

Original Article: Bristol-Myers Squibb And Nektar To Collaborate On Immuno-Oncology Program

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers Squibb And Nektar To Collaborate On Immuno-Oncology Program"

Advertisement
Quick Search
Advertisement
Advertisement